University of North Carolina, Chapel Hill

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of North Carolina, Chapel Hill sits in the top decile of US sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count).

1,109 total trials 108 currently recruiting 881 completed early-phase tilt top decile by trial count

University of North Carolina, Chapel Hill: 1,109 sponsored US clinical trials, 108 recruiting.

University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.

Top-decile sponsor footprint

University of North Carolina, Chapel Hill ranks in the top decile of sponsors by registered trial count (#28 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

881 of 962 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,109 total, page 19 of 23

COMPLETED

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710

COMPLETED NA

Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

NCT00961233

COMPLETED Phase 2

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

NCT00959894

COMPLETED NA

Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis

NCT01031706

COMPLETED NA

Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease

NCT00998244

COMPLETED

Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury

NCT01000766

COMPLETED NA

Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?

NCT01526213

COMPLETED Phase 2

Shoulder Injury Prevention Program in Swimmers

NCT00998777

COMPLETED Phase 2

Pre-Exposure Prophylaxis in YMSM

NCT01033942

COMPLETED Phase 4

FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders

NCT01028820

COMPLETED Phase 1

Multicomponent Cognitive Behavioral Therapy(CBT) for Posttraumatic Stress Disorder (PTSD) and Substance Abuse

NCT01029197

COMPLETED NA

Motivational Enhancement System for Adherence

NCT01009749

COMPLETED NA

The Use of a Language Toolkit for Toddlers

NCT00926510

COMPLETED NA

Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)

NCT00616200

COMPLETED Phase 1

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue

NCT00855088

COMPLETED Phase 1

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

NCT00932282

COMPLETED NA

Nutrition for Chronic Daily Headache

NCT01157208

COMPLETED

Molecular Phenotypes for Cystic Fibrosis Lung Disease

NCT01116414

COMPLETED NA

Study of Parenting Intervention to Prevent Child Obesity

NCT00998348

COMPLETED Phase 2

Burn Healing and Analgesia With Propranolol

NCT00934947

TERMINATED Phase 4

Dexmedetomidine Sedation With Third Molar Surgery

NCT01017237

COMPLETED Phase 2

Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study

NCT00932828

COMPLETED NA

Colon Cancer Prevention Study

NCT00924690

COMPLETED Phase 4

A Pilot Study of Early Postpartum Intrauterine Contraception

NCT00997932

COMPLETED NA

Physiological Effects of Yogurt With Bb12 in Subjects With GI Symptoms Strointestinal Symptoms

NCT01004484

COMPLETED

Linkage to Care - Part II

NCT00891644

COMPLETED Phase 1

A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers

NCT00924768

COMPLETED Phase 1

Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung

NCT00902707

COMPLETED NA

Salivary Inflammatory Biomarkers: Predictors & Comparative Effects of Sonicare/Elite-Flexcare in Stages of Perio Disease

NCT02187185

COMPLETED Phase 2

Oral Immunotherapy (OIT) for Peanut Allergy

NCT00815035

COMPLETED NA

Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)

NCT00858130

COMPLETED

Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin

NCT00878137

COMPLETED Phase 1

Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy

NCT00873782

COMPLETED NA

Project POWER, Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners

NCT01111721

TERMINATED Phase 4

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

NCT00855413

COMPLETED

Treatment De-Intensification and Residual HIV-1 in Youth

NCT00867854

COMPLETED

Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects

NCT00840723

COMPLETED

Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)

NCT01072916

COMPLETED NA

Behavioral, Genetic, and Epigenetic Implications of Dietary Supplementation With Alpha-linolenic Acid in Humans

NCT01634776

COMPLETED Phase 1

A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals

NCT00839124

COMPLETED NA

The Weight-Wise Weight Loss Translation Study

NCT01141348

COMPLETED

ID and Testing Via Friendship Networks

NCT00841360

COMPLETED

The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)

NCT01072903

TERMINATED Phase 1

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

NCT00834899

COMPLETED Phase 1

In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics

NCT00836368

COMPLETED NA

Empowerment Intervention for Young Women - Phase I

NCT00891358

COMPLETED NA

Haufen Diagnostic Biomarkers of BK Renal Disease

NCT01094691

COMPLETED Phase 2

Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

NCT00934362

COMPLETED

Single Dose Truvada in HIV-negative Men and Women

NCT01326221

COMPLETED Early Phase 1

Media Effects Study on Health-Related Content

NCT00775008

← Previous Page 19 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 111
Phase 2 92
Phase 3 13
Phase 4 56

What is open in the University of North Carolina, Chapel Hill pipeline

108 recruiting of 1,109 indexed (10% open); 881 completed (79%).

Phase mix: 69 late (III/IV) vs 203 early (I/II) (early-phase heavy).

Top condition: Obesity (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of North Carolina, Chapel Hill: open-pipeline peers nationwide

Peers matched on 1,109 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share University of North Carolina, Chapel HillUniversity of FloridaWake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiOhio University
University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of North Carolina, Chapel Hill sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,109 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this University of North Carolina, Chapel Hill page

1,109 registered trials is a research-attention snapshot, not an endorsement of University of North Carolina, Chapel Hill or any single study.

  • 108 of University of North Carolina, Chapel Hill's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of North Carolina, Chapel Hill studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of North Carolina, Chapel Hill pipeline card: 1,109 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.